Pfizer halts tanezumab studies on FDA request
Pfizer halts tanezumab studies on FDA request
SAN FRANCISCO (MarketWatch) — Pfizer Inc. said late Monday it suspended studies of tanezumab in the treatment of chronic back pain and diabetes on the request of the U.S. Food and Drug Administration. However, Pfizer will continue to test the drug in other areas, including treatment of cancer pain. The FDA’s request is due to concerns about side effects following reports of adverse events in …
Read more on Market Watch
Related posts:
- U.S. Drug Enforcement Administration Preventing Nursing Home Patients From Getting Pain Medication
- Arthritis Pain Treatment
- Pains Management Let You Get Over Pains Easily and with the Help of PainsManagement.com
- Adhesion Related Disorder Activist Karen Steward Proposes Five Ways to Improve Surgical Consent Process
- Stay Pain-free with Pain Relief Medication